195 related articles for article (PubMed ID: 37465685)
1. Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB.
Chang ZW; Goh YS; Rouers A; Fong SW; Tay MZ; Chavatte JM; Hor PX; Loh CY; Huang Y; Tan YJ; Neo V; Kam IKJ; Yeo NK; Tan EX; Huang D; Wang B; Salleh SNM; Ngoh EZX; Wang CI; Leo YS; Lin RTP; Lye DCB; Young BE; Muthiah M; Ng LFP; Rénia L;
Front Immunol; 2023; 14():1206016. PubMed ID: 37465685
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Variants Omicron BA.4/5 and XBB.1.5 Significantly Escape T Cell Recognition in Solid-organ Transplant Recipients Vaccinated Against the Ancestral Strain.
Halvorson T; Ivison S; Huang Q; Ladua G; Yotis DM; Mannar D; Subramaniam S; Ferreira VH; Kumar D; Belga S; Levings MK;
Transplantation; 2024 Apr; 108(4):e49-e62. PubMed ID: 38012843
[TBL] [Abstract][Full Text] [Related]
3. Humoral and cellular immune responses to COVID-19 mRNA vaccines in immunosuppressed liver transplant recipients.
Nogimori T; Nagatsuka Y; Kobayashi S; Murakami H; Masuta Y; Suzuki K; Tomimaru Y; Noda T; Akita H; Takahama S; Yoshioka Y; Doki Y; Eguchi H; Yamamoto T
Commun Med (Lond); 2024 Feb; 4(1):30. PubMed ID: 38409262
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of humoral and cellular response to three doses of anti-SARS-CoV-2 BNT162b2 vaccine in patients with hematological malignancies and older subjects.
Laquintana V; Mottini C; Marchesi F; Marcozzi B; Terrenato I; Sperandio E; de Latouliere L; Carrieri F; Pimpinelli F; Pontone M; Pellini R; Campo F; Conti L; Accetta C; Mandoj C; Petrone F; Di Bella O; Vujovic B; Morrone A; Compagnone M; Principato E; Pinto E; Papa E; Falcucci P; La Malfa A; Pallocca M; De Marco F; Piaggio G; Ciliberto G; Mengarelli A; di Martino S
Front Immunol; 2023; 14():1221587. PubMed ID: 38343436
[TBL] [Abstract][Full Text] [Related]
5. Boosting compromised SARS-CoV-2-specific immunity with mRNA vaccination in liver transplant recipients.
Luxenburger H; Reeg DB; Lang-Meli J; Reinscheid M; Eisner M; Bettinger D; Oberhardt V; Salimi Alizei E; Wild K; Graeser A; Karl V; Sagar ; Emmerich F; Klein F; Panning M; Huzly D; Bengsch B; Boettler T; Elling R; Thimme R; Hofmann M; Neumann-Haefelin C
J Hepatol; 2023 May; 78(5):1017-1027. PubMed ID: 36804404
[TBL] [Abstract][Full Text] [Related]
6. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
7. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
[TBL] [Abstract][Full Text] [Related]
8. Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA Vaccination.
Catry E; Favresse J; Gillot C; Bayart JL; Frérotte D; Dumonceaux M; Evrard P; Mullier F; Douxfils J; Carlier FM; Closset M
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891450
[TBL] [Abstract][Full Text] [Related]
9. Durability and cross-reactive immune memory to SARS-CoV-2 in individuals 2 years after recovery from COVID-19: a longitudinal cohort study.
Guo L; Zhang Q; Gu X; Ren L; Huang T; Li Y; Zhang H; Liu Y; Zhong J; Wang X; Chen L; Zhang Y; Li D; Fang M; Xu L; Li H; Wang Z; Li H; Bai T; Liu W; Peng Y; Dong T; Cao B; Wang J
Lancet Microbe; 2024 Jan; 5(1):e24-e33. PubMed ID: 38048805
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.
Corominas J; Garriga C; Prenafeta A; Moros A; Cañete M; Barreiro A; González-González L; Madrenas L; Güell I; Clotet B; Izquierdo-Useros N; Raïch-Regué D; Gallemí M; Blanco J; Pradenas E; Trinité B; Prado JG; Blanch-Lombarte O; Pérez-Caballero R; Plana M; Esteban I; Pastor-Quiñones C; Núñez-Costa X; Taleb RA; McSkimming P; Soriano A; Nava J; Anagua JO; Ramos R; Lluch RM; Comes AC; Romero SO; Gomez XM; Sans-Pola C; Moltó J; Benet S; Bailón L; Arribas JR; Borobia AM; Parada JQ; Navarro-Pérez J; Forner Giner MJ; Lucas RO; Jiménez MDMV; Compán SO; Alvarez-Mon M; Troncoso D; Arana-Arri E; Meijide S; Imaz-Ayo N; García PM; de la Villa Martínez S; Fernández SR; Prat T; Torroella È; Ferrer L
Lancet Reg Health Eur; 2023 May; 28():100613. PubMed ID: 37131861
[TBL] [Abstract][Full Text] [Related]
11. A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients.
Tomiyama T; Suzuki R; Harada N; Tamura T; Toshida K; Kosai-Fujimoto Y; Tomino T; Yoshiya S; Nagao Y; Takeishi K; Itoh S; Kobayashi N; Ito H; Yoshio S; Kanto T; Yoshizumi T; Fukuhara T
Front Cell Infect Microbiol; 2023; 13():1197349. PubMed ID: 37260700
[TBL] [Abstract][Full Text] [Related]
12. Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients.
Murray SM; Pose E; Wittner M; Londoño MC; Schaub G; Cook J; Dimitriadis S; Meacham G; Irwin S; Lim Z; Duengelhoef P; Sterneck M; Lohse AW; Perez V; Trivedi P; Bhandal K; Mullish BH; Manousou P; Provine NM; Avitabile E; Carroll M; Tipton T; Healy S; Burra P; Klenerman P; Dunachie S; Kronsteiner B; Maciola AK; Pasqual G; Hernandez-Gea V; Garcia-Pagan JC; Lampertico P; Iavarone M; Gines P; Lütgehetmann M; Schulze Zur Wiesch J; Russo FP; Barnes E; Marjot T;
J Hepatol; 2024 Jan; 80(1):109-123. PubMed ID: 37863203
[TBL] [Abstract][Full Text] [Related]
13. Third Early "Booster" Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses.
Ahmed-Belkacem A; Redjoul R; Brillet R; Ahnou N; Leclerc M; López-Molina DS; Soulier A; Gourgeon A; Rodriguez C; Maury S; Pawlotsky JM; Fourati S
Viruses; 2022 Aug; 14(9):. PubMed ID: 36146735
[TBL] [Abstract][Full Text] [Related]
14. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
15. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
16. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA
Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493
[TBL] [Abstract][Full Text] [Related]
17. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
[TBL] [Abstract][Full Text] [Related]
18. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
[TBL] [Abstract][Full Text] [Related]
20. Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients.
Harberts A; Schaub GM; Ruether DF; Duengelhoef PM; Brehm TT; Karsten H; Fathi A; Jahnke-Triankowski J; Fischer L; Addo MM; Haag F; Luetgehetmann M; Lohse AW; Schulze Zur Wiesch J; Sterneck M
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2558-2566.e5. PubMed ID: 35850415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
